In clinical research, a blood draw or a tissue sample is a valuable raw data. If that sample is damaged in the first minutes after it is taken, no lab test, statistician or software tool can fix it later. 

That is why biospecimen collection deserves the same careful planning as protocol design or site selection. Yet it is often treated as a routine task left to busy site staff. 

In this blog, we will explain what sample quality really means, where it is most often lost, what poor quality costs a study, and what good practice looks like, including the rules that apply in India. 

What “Quality” Really Means for a Biospecimen 

A high-quality sample is not simply one that reached the lab. In biospecimen collection clinical research teams can trust, quality means four things: 

• Fit for purpose: The sample was collected and processed in a way that suits the planned test, whether that is DNA, RNA, protein or living cells. 

• Intact: The molecules being planned to measure have not broken down, and there is enough volume to test. 

• Well documented: Every step, from draw time to freezing time, is recorded and incorporated into robust clinical data management processes so that specimen information remains traceable throughout the study. 

• Ethically sound: The participant gave valid consent, and the chain of custody is unbroken. 

This becomes particularly important in oncology research, where specimen type, processing time and storage conditions can directly affect biomarker analysis. Our guide on biospecimens in emerging oncology research explores these requirements in more detail. A sample that fails any one of these can still produce results. The danger is that those results look real but are not. 

Where Quality Is Lost: The Pre-Analytical Chain 

Most sample problems happen before the sample is ever tested. This stretch, from preparing the participant to delivering the sample to the lab, is called the pre-analytical phase. It accounts for up to 70% of all laboratory errors (PMC review). 

Good biological sample collection depends on getting each link in this chain right: 

Time matters more than many teams realise. According to the NIH, some cancer-related proteins change within 5 to 20 minutes of tissue removal, and estrogen receptor tests show more false negatives when tissue is tested over 24 hours after collection. In one tumour bank, 24.5% of samples frozen within 30 minutes had degraded RNA. At 45 minutes, that rose to 47%. 

The Real Cost of Poor-Quality Samples 

A damaged sample costs far more than the tube it came in. Weak clinical trial sample management shows up in several ways: 

• Rejected samples: Across studies, about 2% of blood samples are rejected by labs, mostly due to clotting, hemolysis, low volume or labelling errors. 

• Lost timepoints: You can redraw a routine sample, but you cannot go back and collect a baseline or a sample from a specific dosing day. 

• Misleading results: Degraded samples can make a biomarker look absent, or present, when it is not. Poor-quality samples can introduce variability that complicates statistical analysis and interpretation, making clinical biostatistics services an important part of evaluating the reliability of study data. 

• Findings that cannot be repeated: Researchers have linked poor sample handling to the wider problem of irreproducible results. 

• Regulatory questions: Gaps in sample records can raise doubts about the integrity of the whole data set. 

Each of these adds time, cost and risk to a study, often long after the sample was taken. 

What Good Collection Practice Looks Like 

The good news is that most quality problems are preventable. Strong biospecimen handling rests on a few simple habits: 

• Clear standard operating procedures that every site follows the same way. Consistent oversight is equally important; our guide to clinical monitoring approaches explains how on-site, remote and risk-based monitoring can support protocol compliance and data quality. 

• Trained site staff who understand why timing and tube choice matter, supported by effective clinical trial site management to maintain consistent procedures across participating locations. 

• Time-stamped records of every step, from draw to freezer. Clinical trial monitoring can help verify that collection, processing, documentation and storage procedures are being followed consistently at participating sites. 

• Temperature-controlled storage and shipping, with logs that prove it. 

• Quality checks on arrival, such as RNA integrity scores and hemolysis checks. 

You do not need to invent these standards. The NCI published the 4th edition of its Best Practices for Biospecimen Resources in 2026, and ISO 20387 sets the international standard for biospecimen management in biobanks. Building your study protocols on these makes your samples easier to trust and easier to share. 

Ethics and Regulation: Getting It Right in India 

Quality is not only scientific. A perfect sample is useless if it was collected or shared the wrong way. 

• Consent: participants must understand how long their samples will be stored, whether they may be used for future research, and their right to refuse. ICMR’s National Ethical Guidelines cover this in a dedicated section on biological materials and biobanking. 

• Export: sending human samples abroad for commercial or contract research follows a DGFT notification and ICMR runs an online portal for the required no-objection certificate. 

• Research collaborations: Transfers under international research projects go through the Health Ministry’s Screening Committee. 

Planning these steps early avoids last-minute delays when samples need to move. 

Choosing the Right Collection Partner 

Many sponsors rely on a partner to collect samples across several sites. For multi-site studies, these activities are part of broader clinical operations, where site coordination, biospecimen logistics and data processes need to work together. These questions help separate a reliable partner from a risky one. 

Question to ask	Why it matters
How many sites do you work with, and do they treat my target patients?	Access to the right patients sets your timeline and sample size.
Are your SOPs the same at every site?	Different methods at different sites make samples hard to compare.
How do you record collection and processing times?	Without time stamps, you cannot prove a sample is fit for purpose.
How do you control temperature during storage and shipping?	Temperature swings are one of the most common causes of damage.
What quality checks do you run before release?	Problems caught early cost far less than failed assays later.
How do you handle consent and export approvals?	Gaps here can block a whole shipment, however good the samples.

Conclusion 

Sample quality is decided at the bedside, not in the lab. The choices made in the first minutes after a draw or biopsy shape every result that follows. 

Sponsors who plan biospecimen collection as carefully as they plan the protocol get data they can trust, and avoid costly repeats, lost timepoints and regulator questions. 

Need reliable samples for your next study? Innovate Research collects and manages biospecimens through its network of hundreds of sites across India, following standardised procedures from draw to delivery. Read more about the role of biospecimens in emerging oncology modalities, or request a proposal. 

FAQs 

How quickly do samples need to be processed after collection? 

It depends on what you plan to measure. Many routine blood chemistry tests stay stable for hours, but some markers change fast. In one study, plasma levels of the cytokine IL-18 rose more than 100-fold when processing was delayed 24 hours at room temperature (PMC). Set time limits for each test in your protocol, not one rule for every sample. 

Should we choose serum or plasma? 

Choose based on the test, and decide before the study starts. Serum comes from blood that has clotted, while plasma comes from blood kept liquid with an additive. The same marker can give different results in each, so switching partway through a study can make data hard to compare. 

How can we tell if a sample is still good? 

Check the records first: collection time, processing time and temperature logs. Then use simple quality checks suited to the sample type, such as a hemolysis check for blood or an RNA integrity score for tissue. A sample without records is a sample of unknown quality. 

Can we use archived or leftover samples for a new study? 

Often, yes, but only if two things are true. The original consent must cover the new use, and there must be records showing how the samples were handled. Without both, the samples carry ethical and scientific risk. 

What should a consent form say about samples? 

It should explain what will be collected, how long it will be stored, whether it may be used for future research or shared with other organisations, and the participant’s right to refuse or withdraw. ICMR’s National Ethical Guidelines set out these points for research in India. 

Can samples collected in India be shipped abroad? 

Yes, with the right approvals. Export for commercial or contract research needs a no-objection certificate through ICMR’s online portal, while international research collaborations go through the Health Ministry’s Screening Committee. Build this step into your timeline from the start. 

Are central labs better than local labs? 

Central labs give consistent methods across all sites, which makes results easier to compare. The trade-off is shipping. A study of blood shipped to a central lab found that temperature during transit affected cell yield and viability, so packaging and courier choice matter (PMC).